TY - JOUR
T1 - The unmet need of psychopharmacological intervention for neuropsychiatric and neurodevelopmental comorbidities in Duchenne muscular dystrophy
T2 - report of 5 workshops
AU - Muntoni, Francesco
AU - De Waele, Liesbeth
AU - Munell, Francina
AU - Schara-Schmidt, Ulrike
AU - Mercuri, Eugenio
AU - Hendriksen, Jos
AU - BIND WP5 working group
AU - DMD Psychopharmaca working group
N1 - Funding Information:
We gratefully acknowledge the European Union Horizon 2020 Framework Programme research and innovation program \u2018Brain Involvement iN Dystrophinopathies\u2019 (grant agreement, 847826), Duchenne UK , Parent Project Muscular Dystrophy , Little Steps and Duchenne Parent Project Netherlands for supporting the BIND scientific project manager who coordinated the workshops (Michelle Wortley); and the Duchenne Parent Project Netherlands, Duchenne Incentive Grant Research Call , which will allow this work to continue.
Publisher Copyright:
© 2026 The Authors
PY - 2026/3/1
Y1 - 2026/3/1
N2 - Brain involvement is a well-recognised feature of Duchenne muscular dystrophy (DMD), presenting with intellectual disability and/or behavioural manifestations. Cumulatively, associated neurodevelopmental comorbidities affect half of the DMD population but receive little attention in standards of care recommendations and clinical practice. Access to pharmacological interventions for emotional and behavioural symptoms is limited, despite the availability of drugs with well-established efficacy. We lack information on appropriate choice, efficacy and safety of psychopharmacological interventions in DMD. Neuromuscular clinicians and neuropsychologists from eight European countries held a series of meetings between 2024 and 2025 to review the range of behavioural and emotional comorbidities observed in their respective DMD clinics and treatment strategies implemented. Each centre provided empirical evidence of the efficacy and safety of psychopharmacological interventions based on their experience. This working group identified comorbidities for which there was full consensus on drug selection, efficacy, and apparent tolerability, as well as areas with inconsistent approaches, underscoring the need for additional evidence.
AB - Brain involvement is a well-recognised feature of Duchenne muscular dystrophy (DMD), presenting with intellectual disability and/or behavioural manifestations. Cumulatively, associated neurodevelopmental comorbidities affect half of the DMD population but receive little attention in standards of care recommendations and clinical practice. Access to pharmacological interventions for emotional and behavioural symptoms is limited, despite the availability of drugs with well-established efficacy. We lack information on appropriate choice, efficacy and safety of psychopharmacological interventions in DMD. Neuromuscular clinicians and neuropsychologists from eight European countries held a series of meetings between 2024 and 2025 to review the range of behavioural and emotional comorbidities observed in their respective DMD clinics and treatment strategies implemented. Each centre provided empirical evidence of the efficacy and safety of psychopharmacological interventions based on their experience. This working group identified comorbidities for which there was full consensus on drug selection, efficacy, and apparent tolerability, as well as areas with inconsistent approaches, underscoring the need for additional evidence.
U2 - 10.1016/j.ejpn.2026.03.011
DO - 10.1016/j.ejpn.2026.03.011
M3 - Article
SN - 1090-3798
VL - 61
SP - 84
EP - 89
JO - European Journal of Paediatric Neurology
JF - European Journal of Paediatric Neurology
ER -